Morgan Stanley Report
OT..... a bit. Sector related. Disease related. Potential Market related. Disease Indication related. OK OK it's not off topic......
Hey Polak.....and ANYONE else interested. Let me know if you want the Morgan Stanley Report for Wyeth from Feb. 19/08 . It can be inboxed easily. The Report focuses on the Alzheimers aspect of Wyeths initiatives. Recall they are the 50% Partner to ELAN with AAB-001 the AD Drug that is currently Dosing in PHASElll while PHASEll is still not even completed. They Initiated the PHASElll from the Data from an 'INTERIM PEEK' of the PHASEll while keeping the Trial Blinded. Only about 8 people in the world have seen the PHASEll Interim Data which is slated to be revealed in July at the ICAD in Chicago. Only the FDA--EMEA--ELAN--Wyeth are privy. The Monitoring Committee is privy to the Safety Data.
This is similar to what Transition & ELAN may do although WYE/ELAN's drug no longer has the options AZD-103 has because of the APOE4 Carriers VE response and the resulting allowances made in the protocols going into Phaselll. In other words AZD-103/ELND005 can still catch up to AAB-001. Pretty much exactly like ELAN CEO Kelly Martin has said repeatedly.
Wyeth & ELAN's drug is very very different being a Biologic and not a Small Molecule but targets the same Amyloid-Beta Plaque that is described in Selkoes Amyloid Cascade much like AZD-103 does.......Dr. Cruz talks about it in Transitions Q2 Conference Call in response to a question from Peter (You'All) Johnson from Ashfield Capital Partners.
All in All a good read for those interested in the Alzheimers Valuations and Risks/Rewards......it also provides Different Case-Scenarios with the in-depth reasoning behind those Scenarios and resulting Share Price Impact.
Actually I already know Polak will want it so its on it's way Polak. BTW did you take RBC's advice and reduce your exposure to MPH Polak?? I kinda thought something wasn't right when Phillipa Omitted MPH from the Quarterly Prognosis of her entire Coverage Universe of 14 Co.'s on Sept. 27th........A GOOD 8 EIGHT DAYS BEFORE her Downgrade and Target Slashing and her "opinion of a lack of meaningful phase II data".... and..... "We believe there is AT LEAST a 50% chance of failure due to our view of a lack of meaningful phase II results."
Hope so. GPP......